Cognitive functioning in cancer patients: effect of previous treatment.
Neuropsychological analysis of 47 cancer patients with widely metastatic disease and significant previous treatment indicated that 34% had cognitive deficits. Previous treatment with biologic response modifiers was associated with a 53% frequency of cognitive abnormalities, whereas only 18% of patients who were never treated with biologics had such impairments. The possibility that neurobehavioral abnormalities will result from metastatic disease and treatment regimens is an important factor in determining the risks and benefits of therapy.
Meyers
C A
CA
Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Abbruzzese
J L
JL
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003071:Cognition / Q000502:physiology*; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology*; D009483:Neuropsychological Tests
D000970:Antineoplastic Agents; D007155:Immunologic Factors